Rhinitis – Pipeline Review, H2 2012

Rhinitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Rhinitis - Pipeline Review, H2 2012', provides an overview of the Rhinitis therapeutic pipeline. This report provides information on the therapeutic development for Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinitis. 'Rhinitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rhinitis.
- A review of the Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rhinitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Rhinitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rhinitis pipeline depth and focus of Rhinitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhinitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Rhinitis 7
Rhinitis Therapeutics under Development by Companies 9
Rhinitis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Rhinitis Therapeutics – Products under Development by Companies 15
Rhinitis Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Rhinitis Therapeutics Development 17
GlaxoSmithKline plc 17
Meda AB 18
Revance Therapeutics, Inc. 19
Stallergenes S.A. 20
Rhinitis – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
SB705498 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
OX-NLA - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Epicutaneous Allergen Patch - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RT401 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Ragweed Sublingual Immunotherapy Tablet - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HCP0703 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Rhinitis Therapeutics – Drug Profile Updates 34
Rhinitis Therapeutics – Discontinued Products 35
Rhinitis Therapeutics - Dormant Products 36
Rhinitis – Product Development Milestones 37
Featured News & Press Releases 37
Jun 14, 2012: Shionogi Announces Initial Data From Phase IIb Study Of S-555739 37
Dec 22, 2011: Ampio Pharmaceuticals Receives Canadian Composition Of Matter Patent For Ampion 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Rhinitis, H2 2012 7
Products under Development for Rhinitis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
GlaxoSmithKline plc, H2 2012 17
Meda AB, H2 2012 18
Revance Therapeutics, Inc., H2 2012 19
Stallergenes S.A., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Rhinitis Therapeutics – Drug Profile Updates 34
Rhinitis Therapeutics – Discontinued Products 35
Rhinitis Therapeutics – Dormant Products 36

List of Figures
Number of Products under Development for Rhinitis, H2 2012 7
Products under Development for Rhinitis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25